✨ Your Portfolio is fetched and updated from zerodha.
Small Pharmaceuticals

Syncom Formulations (India) Ltd.

SYNCOMF

Market Cap
₹1,653 Cr.
P/E
42.24

Syncom Formulations (India) Ltd.

  • Syncom Formulations
  • Beta Drugs
  • Jagsonpal Pharma
FAQs on Syncom Formulations (India) Ltd. Shareprice

Syncom Formulations has given better returns compared to its competitors.
Syncom Formulations has grown at ~43.82% over the last 7yrs while peers have grown at a median rate of 8.81%

Syncom Formulations is not expensive.
Latest PE of Syncom Formulations is 42.24, while 3 year average PE is 49.52.
Also latest EV/EBITDA of Syncom Formulations is 35.39 while 3yr average is 47.34.

View FAQ's On Business
Growth Table
  • Syncom Formulations (India) Ltd.
  • Beta Drugs
  • Jagsonpal Pharma
Balance Sheet
  • Syncom Formulations (India) Ltd.
  • Beta Drugs
  • Jagsonpal Pharma
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Syncom Formulations (India) Ltd.
  • Beta Drugs
  • Jagsonpal Pharma
Cash Flow
  • Syncom Formulations (India) Ltd.
  • Beta Drugs
  • Jagsonpal Pharma
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Syncom Formulations (India) Ltd.
  • Beta Drugs
  • Jagsonpal Pharma
Quarterly Results
  • Syncom Formulations (India) Ltd.
  • Beta Drugs
  • Jagsonpal Pharma
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Rhapson method.
Learn how to use Reverse DCF
FAQs on Syncom Formulations (India) Ltd. Financials

Balance sheet of Syncom Formulations is strong.
It shouldn't have solvency or liquidity issues.

Yes, The debt of Syncom Formulations is increasing.
Latest debt of Syncom Formulations is ₹2.36 Crs as of Sep-24.
This is greater than Mar-24 when it was -₹63 Crs.

Yes, profit is increasing.
The profit of Syncom Formulations is ₹39.15 Crs for TTM, ₹25.31 Crs for Mar 2024 and ₹20.07 Crs for Mar 2023.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Syncom Formulations latest dividend payout ratio is 14.05% and 3yr average dividend payout ratio is 14.05%

Companies resources are allocated to majorly productive assets like Plant & Machinery and unproductive assets like Cash & Short Term Investments, Accounts Receivable

View FAQ's On Shareholding
Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech